Patient Name:							Health C	enter:					
STANDARD INFORMATION LO	G: 12-Do	se Isonia	zid-Rifa _l	pentine La	tent TB	Infection	Treatme	nt Dose ar	nd Symp	tom Monit	toring		
PF No: Age:	Sex:	M/F E	thnicity:	Hispanic /	Non-Hisp	panic Ra	nce:	We	eight:	lbs	Height:	f	t/inches
Treatment reason: \Box Contact \Box C	Corrections	□Hon	neless	□Refuge	e □Fo	reign-bor	n 🗆	Convertor	· [Oose: INH	mg	RPT_	mg
*Check ✓ symptoms or events re	ported on	the listed	l date; o	therwise, l	eave blar	ık.							
Date: Dose:	//_ 0 Baseline	//	_/_/	_/_/	//	_/_/_	_/_/_	_/_/_	_/_/_	_/_/_	//	_/_/_	//12
Directly Observed Therapy (DOT) received													
No adverse reaction													
Loss of appetite													
Nausea or vomiting													
Yellow eyes or skin													
Diarrhea													
Rash/hives													
Fever or chills													
Sore muscles or joints													
Numbness or tingling													
Fatigue													
Dizziness/fainting													
Abdominal pain													
(Other)													
Treatment stopped or held (complete AE report on last page)													
	NH-RPT t Lost to foll Death Other Adverse ev	reatment ow-up ent (fill o	Date ut last pa	//_ ge if treatn men	nent stopp	ed for AE))						

Patient Name:	Health Center:				
(CHECK (√) or COMPLETE ALL SECTIONS THAT APPLY): MEDICAL RISK FACTORS AND HISTORY: □ Diabetes (type) □ Chronic renal disease (□on dialysis)	HIV STATUS: □ Positive □ Negative	□Unknown/	Not tested		
Immunocompromised (diagnosis)	POPULATION RISK F MONTHS: Homeless or SRO/She Incarcerated (prison, j Long-term care facilit Health care worker Migrant worker Employee - homeless Employee - correction Employee - other high Other	elter resident ail, juvenile ha y resident shelter al facility -risk setting _	ull)		
MEDICATIONS:	Liver function tests*	Result	Result	Result	Result
☐ Warfarin (blood thinner) ☐ Statins (cholesterol-lowering drugs)	Date (mm/dd/yyyy)				
☐ Methadone	AST (0-35 U/L)				
☐Diabetes medicines (list):	ALT (0 – 35 U/L)				
□ Blood pressure medications (list):	Alk Phos (36 – 92 U/L)				
TNF-α inhibitors* (biologic agents used for rheumatoid arthritis, psoriasis, and other auto-immune inflammatory diseases)	T. Bili (0.3 - 1.2 mg/dL)				
Other (list):	(Other)				
□None	(Strict)	-			

^{*} ertanecept, adalimumab, infliximab, golimumab, pegsunercept, certolizumab

 $[\]ensuremath{^*}$ If liver function tests are done, please report values.

tient Name:						Health Center:	
LL OUT <u>ONLY</u>	FOR AD	VERSE EVENT	ΓS:				
mptom Rx Related Stopped DOSE or Held	Date Symptom Began	Symptom Onset after Dose	Symptom D	uration	Hospital Admission	Medication Re-challenge	Outcome
☐ Yes ☐ No		☐ < 2 hrs ☐ 2 − 48hrs ☐ > 48hrs ☐ Unknown	□ < 1 day □ > 1 day □ Unknown		☐ Yes ☐ No ☐ Unknown	☐ Yes ☐ INH re-challenged ☐ RIF/RPT re- challenged ☐ No ☐ Unknown	☐ Continue INH/RPT ☐ Switch to INH for 6 or 9 month ☐ Switch to Rifampin for 4 month ☐ Stopped any LTBI treatment ☐ Unknown
☐ Yes ☐ No		☐ < 2 hrs ☐ 2 − 48hrs ☐ > 48hrs ☐ Unknown	□ <1 day □ >1 day □ Unknown		☐ Yes ☐ No ☐ Unknown	☐ Yes ☐ INH re-challenged ☐ RIF/RPT re- challenged ☐ No ☐ Halmann	☐ Continue INH/RPT ☐ Switch to INH for 6 or 9 month ☐ Switch to Rifampin for 4 month ☐ Stopped any LTBI Treatment ☐ Unknown
						☐ Unknown t in relation to last INH-RPT dose	, duration and resolution and any oth
	dical condi	tions, medication	rse event, includins). Enter comments				, duration and resolution and any oth
actors (other me	s (only if a	tions, medication	18). Enter comments		low:	t in relation to last INH-RPT dose	, duration and resolution and any other
actors (other me aboratory Value Complete Bloo Date (mm/dd/yy	s (only if a	pplicable)	Va	in text box be	Chem Date	t in relation to last INH-RPT dose	
actors (other me aboratory Value Complete Bloo Date (mm/dd/yy Hemoglobin (N	s (only if a Count	pplicable)	Va Va g/dL)	in text box be	Chem Date Na (S	istry Panel (mm/dd/yyyy) odium) (136–150 meq/L)	
caboratory Value Complete Bloo Date (mm/dd/yy Hemoglobin (M	s (only if a l Count /y) Ien: 14–17 g/en: 41%–51%	pplicable) dL, Women: 12–16, Women: 36%–47	Va Va g/dL)	in text box be	Chem Date Na (S	istry Panel (mm/dd/yyyy) odium) (136–150 meq/L) tassium) (3.5–5.0 meq/L)	
actors (other me aboratory Value Complete Bloo Date (mm/dd/yy Hemoglobin (M Hematocrit (M White Blood C	s (only if a d Count y) Jen: 14–17 g/ en: 41%–51% ell Count (ell count (el	pplicable) dL, Women: 12–16, Women: 36%–47	Va Va g/dL)	in text box be	Chem Date Na (S K (Po	istry Panel (mm/dd/yyyy) odium) (136–150 meq/L) tassium) (3.5–5.0 meq/L) (urea nitrogen) (8–20 mg/dL)	
caboratory Value Complete Bloo Date (mm/dd/yy Hemoglobin (M	s (only if a d Count y) Jen: 14–17 g/ en: 41%–51% ell Count (ell count (el	pplicable) dL, Women: 12–16, Women: 36%–47	Va Va g/dL)	in text box be	Chem Date Na (S K (Po	t in relation to last INH-RPT dose sistry Panel (mm/dd/yyyy) odium) (136–150 meq/L) stassium) (3.5–5.0 meq/L) (urea nitrogen) (8–20 mg/dL) reatinine) (0.7 – 1.3 mg/dL)	